NeuBase Therapeutics Inc
F:O7PA
NeuBase Therapeutics Inc
Operating Expenses
NeuBase Therapeutics Inc
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
NeuBase Therapeutics Inc
F:O7PA
|
Operating Expenses
-$13.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-11%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Expenses
-$22.7B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-7%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Expenses
-$11.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Expenses
-$13.8B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Expenses
-$5.6B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-16%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Expenses
-$8.5B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-13%
|
|
NeuBase Therapeutics Inc
Glance View
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 33 full-time employees. The firm is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.
See Also
What is NeuBase Therapeutics Inc's Operating Expenses?
Operating Expenses
-13.4m
USD
Based on the financial report for Sep 30, 2023, NeuBase Therapeutics Inc's Operating Expenses amounts to -13.4m USD.
What is NeuBase Therapeutics Inc's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-11%
Over the last year, the Operating Expenses growth was 60%. The average annual Operating Expenses growth rates for NeuBase Therapeutics Inc have been 8% over the past three years , -8% over the past five years , and -11% over the past ten years .
